Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.

Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Okada K, Kainuma M, Kajiwara E, Takahashi K, Satoh T, Hayashi J.

J Viral Hepat. 2013 Dec;20(12):838-46. doi: 10.1111/jvh.12109. Epub 2013 May 26.

PMID:
24304453
2.

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.

Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J.

J Hepatol. 2012 Sep;57(3):534-40. doi: 10.1016/j.jhep.2012.04.027. Epub 2012 May 18.

PMID:
22613000
3.

Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.

Del Campo JA, Ampuero J, Rojas L, Conde M, Rojas A, Maraver M, Millán R, García-Valdecasas M, García-Lozano JR, González-Escribano MF, Romero-Gómez M.

Aliment Pharmacol Ther. 2013 Jan;37(1):74-80. doi: 10.1111/apt.12113. Epub 2012 Nov 5.

4.

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.

Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N.

Antivir Ther. 2011;16(5):685-94. doi: 10.3851/IMP1796.

PMID:
21817190
5.

ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.

Matsuura K, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M.

J Viral Hepat. 2014 Jul;21(7):466-74. doi: 10.1111/jvh.12171. Epub 2013 Sep 3.

PMID:
24750345
6.

Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, Lai CL, Yuen MF.

J Viral Hepat. 2013 Jul;20(7):470-7. doi: 10.1111/jvh.12047. Epub 2013 Apr 12.

PMID:
23730840
7.

Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.

Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D'Avolio A.

Arch Virol. 2015 Aug;160(8):2009-17. doi: 10.1007/s00705-015-2482-3. Epub 2015 Jun 10.

PMID:
26060059
8.

Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.

Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M, Merta D, Viklicky O, Spicak J, Jirsa M.

World J Gastroenterol. 2015 May 14;21(18):5496-504. doi: 10.3748/wjg.v21.i18.5496.

9.

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.

Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, Arai M, Fujiwara K, Imazeki F, Yokosuka O.

Viruses. 2012 Aug;4(8):1264-78. doi: 10.3390/v4081264. Epub 2012 Aug 14.

10.

Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C.

Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Nakatsuka K, Kawamoto C, Iwakiri K, Aizawa Y, Sakamoto C.

Intern Med. 2015;54(2):119-26. doi: 10.2169/internalmedicine.54.3066. Epub 2015 Jan 15.

11.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
12.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
13.

IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.

Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T.

World J Gastroenterol. 2012 Sep 21;18(35):4892-7.

14.

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.

Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H, Iijima H, Nishiguchi S.

J Gastroenterol. 2014 Aug;49(8):1253-63. doi: 10.1007/s00535-013-0884-0. Epub 2013 Sep 25.

15.

KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.

Umemura T, Ota M, Katsuyama Y, Wada S, Mori H, Maruyama A, Shibata S, Nozawa Y, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, Kamijo A, Kobayashi M, Takamatsu M, Yoshizawa K, Kiyosawa K, Tanaka E.

Hum Immunol. 2014 Aug;75(8):822-6. doi: 10.1016/j.humimm.2014.06.003. Epub 2014 Jun 11.

PMID:
24929144
16.

[Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].

Xu H, Guo LL, He LL, Chen Y, Liu K, Lei BJ, Lei XZ.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 Nov;43(6):855-9. Chinese.

PMID:
23387213
17.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

18.

Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.

Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ.

J Gastroenterol Hepatol. 2014 Jan;29(1):102-9. doi: 10.1111/jgh.12329.

PMID:
23829453
19.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 May;33(10):1162-72. doi: 10.1111/j.1365-2036.2011.04635.x. Epub 2011 Mar 28.

20.

Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?

Veillon P, Fouchard-Hubert I, Larrey D, Dao MT, D'alteroche L, Boyer-Darrigand N, Picard N, Le Guillou-Guillemette H, Saulnier P, Ducancelle A, Loustaud-Ratti V, Lunel-Fabiani F.

J Interferon Cytokine Res. 2016 Mar;36(3):204-14. doi: 10.1089/jir.2015.0131. Epub 2015 Dec 24.

PMID:
26700738

Supplemental Content

Support Center